在子宫内膜癌中,FKBP38的表达水平通过与Bcl-2的相互作用决定了对帕克利塔塞尔的耐药性
Yunjing Yan1, Yimei Lai2, Minyi Tang3
1Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, China; Center for Cancer Immunology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Biochemical pharmacology
|October 23, 2025
概括
线粒体蛋白质FKBP38在子宫内膜癌 (EC) 中降低,导致化疗耐药性. 恢复FKBP38可以通过稳定线粒体和促进亡来克服帕克利塔塞尔耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 子宫内膜癌 (EC) 经常发展出耐化疗,需要新的治疗策略.
- FKBP38是一种线粒体伴侣,在其他癌症中表现出改变的表达.
- 在人体EC组织中观察到FKBP38的减少表达.
研究的目的:
- 调查FKBP38在子宫内膜癌中帕克利塔塞尔耐药性的作用.
- 探索FKBP38影响化疗反应的机制.
- 评估FKBP38作为EC治疗的潜在生物标志物.
主要方法:
- 在人体EC组织中分析FKBP38表达.
- 在EC细胞系和异种移植模型中FKBP38敲击.
- 对帕克利塔塞尔敏感性和诱导亡的评估.
- 共同免疫沉用于研究蛋白质相互作用 (FKBP38,Bcl-2,Bad).
主要成果:
- 减少FKBP38表达与接受化疗的EC患者的生存率差相关.
- FKBP38 Knockdown 增加了帕克利塔塞尔耐药性,并降低了治疗疗效.
- FKBP38与Bcl-2相互作用,稳定了线粒体功能,并抑制了帕克利塔塞尔诱导的亡.
- FKBP38的淘汰改变了Bcl-2/Bad的相互作用,影响了亡.
结论:
- FKBP38在克服子宫内膜癌中帕克利塔塞尔耐药性的过程中起着至关重要的作用.
- 通过与Bcl-2的相互作用,FKBP38通过维护线粒体功能来抑制抵抗.
- 在欧洲,FKBP38代表了针对性抗代谢物治疗的潜在生物标志物.
相关概念视频
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K